title: Angiotensin converting enzyme inhibitors and pulmonary hypertension.
abstract: OBJECTIVE
  To evaluate the efficacy of angiotensin converting enzyme inhibitors Enalapril, Fosonopril and Moexipril on mean and systolic pulmonary artery pressure.
  
  
  METHODS
  The study included Ill patients with chronic obstructive bronchopneumopathies associated with arterial hypertension and mild to moderate heart failure (NYHA I-II class). The patients were examined at baseline and after 60 days of treatment. The central hemodynamic parameters and mean and systolic pulmonary artery pressure were studied by Doppler echocardiography (Phillips HD11XE). The pulmonary artery was viewed by left parasternal approach - cross section of the aorta. The following were measured: pulmonary artery flow acceleration and deceleration time (pafAT/ pafDT), right ventricular izovolumetric relaxation time (IVRT), mean and peak pulmonary blood flow velocities, right ventricular/pulmonary artery systolic pressure (RV/ PASP). The mean pulmonary artery pressure (MPAP) was estimated based on pulmonary flow acceleration time and right ventricular ejection time.
  
  
  RESULTS
  Following the treatment with angiotensin converting enzyme inhibitors a positive dynamics of SF pattern close to the normal one - a domelike contour with the maximum almost in the middle of diastole was noticed.
  
  
  CONCLUSIONS
  the quantitative estimation revealed the considerable reduction in pulmonary artery systolic pressure (PASP) (from 46.3 +/- 3.3 mmHg at baseline to 32.1 +/- 2.6 mmHg after treatment, p < 0.01) and MPAP - from 26.7 +/- 3.2 mmHg at baseline to 23.2 +/- 2.6 mmHg after treatment, p
authors.affiliation: IMSP Institute of Phthisiopneumology Chiril Draganiuc, Chisinau.
authors.forename: C
authors.initials: C
authors.lastname: Martiniuc
authors.forename: A
authors.initials: A
authors.lastname: Braniste
authors.forename: T
authors.initials: T
authors.lastname: Braniste
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D017328:Fosinopril / Q000627:therapeutic use*; D006333:Heart Failure / Q000150:complications / Q000209:etiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D044005:Tetrahydroisoquinolines; D004656:Enalapril; D017328:Fosinopril; C058302:moexipril